U.S.-based Amgen Inc. announced an exclusive agreement with Daiichi Sankyo for the commercialization of nine biosimilars in Japan including biosimilars of AbbVie’s Humira and Roche Holding's Avastin and Herceptin.
Under the terms of the agreement, Amgen will remain responsible for the development and manufacturing of the biosimilars. Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialization in Japan.
Amgen will retain all additional distribution and commercialization rights for the biosimilar programs outside of Japan.
Read the Amgen press release